A diagnostic method for the prediction of tumor prognosis including the likelihood of formation of metastases or of relapse or local recurrence in tumor related diseases in a mammal and the provision of a therapy recommendation for a patient the enzyme activity of key enzymes of the energy metabolism is determined in fresh tumor tissue or fresh tumor cell mass after 24 hours incubation in a cell culture medium. Incubation reduces nutrition, drug and biopsy/surgery effects on the energy metabolism of the tissue slices or the cell mass. The quotients of enzyme activity of anaerobic enzymes are put in ratio to the enzyme activity of aerobic enzymes or vice versa. Said ratio can be taken into account for prognosis of metastasis and a therapy recommendation.

Methods are disclosed herein for identifying a compound of use in treating a condition treatable by metformin. The methods include determining if the test compound binds a subunit of the mitochondrial electron transport complex IV, and/or alters the function of the mitochondrial electron transport complex IV. Methods for treating a subject with a condition treatable by metformin, are also disclosed. In some embodiments, the condition is type II diabetes.

The present invention relates to methods of diagnosing samples as well as various microfluidic, microcentrifuge and microfilter devices. In one embodiment, the present invention provides a method of diagnosing neurodegenerative diseases using mitochondrial and/or platelet samples. In another embodiment, the present invention provides a microfluidic device that selectively captures and analyzes a desired amount of target biological particle.

The present invention relates to methods of diagnosing samples as well as various microfluidic, microcentrifuge and microfilter devices. In one embodiment, the present invention provides a method of diagnosing neurodegenerative diseases using mitochondrial and/or platelet samples. In another embodiment, the present invention provides a microfluidic device that selectively captures and analyzes a desired amount of target biological particle.

The present disclosure relates to the treatment of Parkinson's disease with granulocyte-macrophage colony-stimulating factor, as well as diagnostic, prognostic and patient selection methods.

The present invention relates to methods of diagnosing samples as well as various microfluidic, microcentrifuge and microfilter devices. In one embodiment, the present invention provides a method of diagnosing neurodegenerative diseases using mitochondrial and/or platelet samples. In another embodiment, the present invention provides a microfluidic device that selectively captures and analyzes a desired amount of target biological particle.

A method of diagnosing the likelihood of recurrence of clear cell renal cell carcinoma is provided. The method involves a) detecting the gene expression signatures of mitochondrial electron transport chain subunits, mitochondrial ribosomal proteins, major histocompatibility complex class II (MHC-II) proteins or combinations thereof in a kidney tumor tissue sample; and b) determining that the subject has an elevated risk of recurrence of clear cell renal cell carcinoma if the gene expression signatures include certain sequences. In another embodiment, the method uses copper levels to diagnose the likelihood of recurrence of clear cell renal cell carcinoma.

This disclosure provides methods, systems, and compositions of matter for studying solvent accessibility and three-dimensional structure of biological molecules. A plasma can be used to generate marker radicals, which can interact with a biological molecule and mark the solvent-accessible portions of the biological molecule.

A method of assessing mitochondria bioenergetics includes obtaining a frozen tissue or frozen biofluid sample of an individual and measuring mitochondria bioenergetics of the frozen tissue or frozen biofluid sample using a substrate for the frozen tissue or biofluid sample. The substrate may include at least one of Glucose; Alamethicin, Nicotinamide adenine dinucleotide (H), and Cytochrome C; Succinate and Rotenone; or Ascorbate+TMPD (Tetramethyl phenylenediamine).